1 min read
Add as a preferred source on Google

Retension Pharmaceuticals Posts $7.33 Q3 GAAP Loss Per Share

Cash and cash equivalents totaled $9.2 million at Sept. 30, excluding about $45.1 million in net IPO proceeds from a deal that closed after the quarter.

An unmarked vial stands beside a partly drained glass vessel / TokenPost.ai
An unmarked vial stands beside a partly drained glass vessel / TokenPost.ai

Retension Pharmaceuticals, Inc. (RTSN) recorded a GAAP loss of $7.33 per share for the third quarter of 2026. Cash and cash equivalents totaled $9.2 million on Sept. 30, compared with $18.9 million on Dec. 31, 2025.

The quarter-end cash balance excludes net proceeds from the company’s IPO, which closed after the quarter. On a pro forma basis, including about $45.1 million in net IPO proceeds, cash and cash equivalents as of Sept. 30 were about $54.3 million.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…